Psilocybin-assisted psychotherapy for substance use disorders as a complex intervention: A systematic review of efficacy, mechanisms and psychotherapeutic frameworks.
Lana Strika-Bruneau, Chérine Elhssaini, Baptiste Fauvel et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review synthesized clinical studies of psychedelic-assisted psychotherapy for substance use disorders, focusing on treatment frameworks, dosing, safety, and possible mechanisms. Seventeen studies, including 10 primary clinical trials, met the criteria; all trials examined psilocybin within structured psychotherapy, mainly cognitive-behavioral or third-wave approaches. The review found that treatment was associated with reduced substance use, higher abstinence rates, and improved psychological well-being, but results were heterogeneous and dependent on study design. Evidence was strongest in trials combining repeated high-dose sessions with extended psychotherapeutic engagement, though the authors characterize the intervention as promising but still emerging.
Key findings
- The review included 17 studies, encompassing 10 primary clinical trials: ten on alcohol, five on tobacco, one on methamphetamine, and one on cocaine use disorder.
- All trials studied psilocybin within structured psychotherapeutic protocols, primarily cognitive-behavioral and third-wave approaches.
- Psilocybin-assisted psychotherapy was associated with reduced substance use, higher abstinence rates, and improved psychological well-being, with heterogeneous, design-dependent findings.
- Trials combining repeated high-dose sessions with extended psychotherapy consistently reported sustained clinical benefits.
Why it matters
The review frames psychedelic-assisted psychotherapy as an integrated intervention in which medication, subjective experience, psychotherapy, and context may jointly shape outcomes. This distinction matters when interpreting efficacy and designing future studies: results cannot be attributed to the drug alone. The evidence spans several substance use disorders, but remains limited to psilocybin-based protocols and is not yet sufficiently consistent to establish broad effectiveness.
What to keep in mind
The clinical evidence is heterogeneous and design-dependent, and all included trials investigated psilocybin, limiting conclusions about other psychedelics. The review identifies a need for larger controlled trials, active comparators, longer follow-up, and systematic study of psychotherapeutic and contextual mechanisms.